ClinicalTrials.gg
RecruitingNCT07794982Updated Oct 20, 2026

Sodium Oxybate for Postoperative Sleep Disturbance After Thoracic Surgery

An interventional study of sodium oxybate and Placebo in Thoracic Surgical Procedures, sponsored by Jingsheng Lou. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Jingsheng Lou · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 20, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a single-center, randomized, double-blind, placebo-controlled trial. Three hundred-sixty adult patients undergoing elective thoracoscopic surgery will be randomly allocated at a 1:1 ratio to receive either intraoperative sodium oxybate or placebo. The primary objective is to compare postoperative sleep quality between the two groups. Secondary outcomes include postoperative pain scores, incidence of adverse events and other peri-operative indicators.

Read the detailed description

Postoperative sleep disturbance is common after thoracoscopic surgery, which may aggravate pain response and impair postoperative recovery. Sodium oxybate is a sedative-hypnotic agent. This trial intends to explore whether intraoperative administration of sodium oxybate can improve postoperative sleep quality in surgical patients, and to evaluate its peri-operative safety.

02

Conditions studied

  • Thoracic Surgical Procedures

Keywords

  • sodium oxybate
  • postoperative sleep quality
  • thoracoscopic surgery
  • peri-operative anesthesia
03

In context

Lead sponsor

This is the only study on the registry with Jingsheng Lou as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 20, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients scheduled for elective VATS lobectomy or segmentectomy under general anesthesia, who provide written , with anticipated surgical duration > 1 hour.
  • Age ≥18 years old.
  • (ASA) physical status Ⅰ-Ⅲ.
  • Baseline cognitive function: (MMSE) score ≥ 17, adjusted for educational level.

Exclusion criteria

Exclusion Criteria:

  • History of chronic alcohol abuse or illicit substance use.
  • Surgical completion time at or after 20:00.
  • History of central nervous system diseases (epilepsy, Parkinson's disease, dementia, prior stroke) or prior neurosurgical procedures.
  • Post-operative unplanned intensive care unit (ICU) admission.
  • Regular pre-operative use of sodium oxybate, benzodiazepines or other potent central nervous system depressants, unless discontinued for at least 5 elimination half-lives before surgery.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    Sodium oxybate group

    Intravenous sodium oxybate administered during general anesthesia

    Drug: sodium oxybate

  • Placebo comparator
    Placebo group

    Intravenous placebo administered during general anesthesia

    Drug: Placebo

Interventions

  • Intravenous administration during general anesthesia

  • DrugPlacebo

    Intravenous administration during general anesthesia

06

What researchers measure

Primary outcomes

  1. Subjective sleep quality on Post-Operative Day 1 (POD1)

    Subjective sleep quality on Post-Operative Day 1 (POD1), measured by the Richards-Campbell Sleep Questionnaire (RCSQ) total score. The RCSQ total score is the mean value of the first 5 items, ranging from 0 to 100. Higher scores indicate better subjective sleep quality.

    Time frame: Morning of Post-Operative Day 1 (POD1)

Secondary outcomes

  1. Sleep efficiency (SE%)

    Sleep efficiency (SE%) derived from wrist-worn actigraphy.

    Time frame: First Post-Operative Night

  2. Total sleep time (TST, minutes)

    Total sleep time (TST, minutes) derived from wrist-worn actigraphy.

    Time frame: First Post-Operative Night

  3. Wake After Sleep Onset (WASO, minutes)

    Wake After Sleep Onset (WASO, minutes) derived from wrist-worn actigraphy.

    Time frame: First Post-Operative Night

  4. Sleep Latency (SL, minutes)

    Sleep Latency (SL, minutes) derived from wrist-worn actigraphy.

    Time frame: First Post-Operative Night

Other outcomes

  1. Incidence and severity of postoperative delirium

    Incidence and severity of postoperative delirium assessed by the 3-Minute Diagnostic Interview for Confusion Assessment Method-Defined Delirium (3D-CAM). This tool yields a binary diagnosis of delirium (present or absent), as well as grading for delirium severity.

    Time frame: Twice daily (Morning 08:00-10:00 and Evening 18:00-20:00), covering Post-Operative Day 1 (POD1), Post-Operative Day 2 (POD2), Post-Operative Day 3 (POD3)

  2. Total intraoperative consumption of anesthetic agents

    Cumulative intraoperative consumption of propofol and remifentanil.

    Time frame: Intraoperative period

  3. Post-operative Quality of Recovery-15 (QoR-15) score

    Post-operative recovery quality assessed by the Post-operative Quality of Recovery-15 (QoR-15) questionnaire. The total score ranges from 0 to 150. Higher scores indicate better postoperative recovery quality.

    Time frame: Morning of Post-Operative Day 3 (POD3)

  4. Incidence of peri-operative adverse events

    From study drug administration to hospital discharge, up to POD7 Description: Postoperative nausea and vomiting (PONV); respiratory depression (SpO2 \<90% lasting \>2 min); delayed emergence (Steward recovery score \<4 lasting \>30 min post-extubation); bradycardia (HR \<50 bpm); hypothermia (core temp \<35.5℃); electrolyte disorders (hypokalemia, hyponatremia); and Serious Adverse Events (SAEs).

    Time frame: Incidence of peri-operative adverse events

  5. Intra-operative core body temperature

    Intra-operative core body temperature measured during surgery.

    Time frame: From completion of endotracheal intubation until the end of surgical procedure

  6. Incidence and severity of post-anesthetic shivering

    Incidence and severity grading of post-anesthetic shivering.

    Time frame: From the end of surgical procedure until prior to ward transfer

  7. Fasting blood glucose

    Peripheral fasting blood glucose concentration.

    Time frame: Baseline (morning on the day of surgery), morning of Post-Operative Day 1 (POD1))

  8. Blood lactate

    Peripheral blood lactate concentration.

    Time frame: Baseline (morning on the day surgery, fasting state), morning of Post-Operative Day 1 (POD1)

07

Study locations

1 of 1 sites recruiting
  • Chinese PLA General Hospital
    Beijing, 100853, China
    Recruiting
    • Jiangbei Cao, MD · Contactcjb2000@sina.com · +86-10-01066937485
    • Weixing Zhao, MD · Contact1325859408@qq.com · +86-10-01066937485
    • Jiangbei Cao, MD · Sub investigator
    • Weixing Zhao, MD · Sub investigator
    • Mingyu Zhang · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2026 (actual). Primary completion is estimated for Dec 2027, 15 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Oct 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2026
First posted
Aug 31, 2026
StartActual
Sep 1, 2026was Aug 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 20, 2026
Sites
Chinese PLA General Hospital is now Recruiting
Oct 20, 2026
Start date
Aug 2026→Sep 1, 2026 (actual)
Oct 20, 2026
Eligibility
Minimum age 65 Years→18 Years; 1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedAge ≥ 6518 years old.
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Not yet recruiting→Recruiting
    Chinese PLA General Hospital is now Recruiting
    Start date Aug 2026→Sep 1, 2026 (now actual)
    Eligibility Minimum age 65 Years→18 Years; 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedAge ≥ 6518 years old.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07794982
Lead sponsor
Jingsheng Lou
Responsible party
Jingsheng Lou (Professor, Department of Anesthesiology, Chinese PLA General Hospital) — Sponsor-investigator
First posted
Aug 31, 2026
Start date
Sep 1, 2026
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Jiangbei Cao, MD
Contact
cjb2000@sina.com
+86-10-01066937485
Weixing Zhao, MD
Contact
1325859408@qq.com
+86-10-01066937485
Jiangbei Cao, MD
principal investigator · Chinese PLA General Hospital
Weixing Zhao, MD
study director · Chinese PLA General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium Oxybate

Start the discussion